GSK and UCL team up

GlaxoSmithKline (GSK) and University College London's Institute of Ophthalmology have agreed a deal in which the Institute will investigate the potential of compounds provided by GSK's ophthalmic unit, Ophthiris.

Related Content:

Articles

An eye towards plateau iris and its implications for patients

Diagnosing Alzheimer’s disease: Ophthalmologists have role in early detection

The relationship between myopia and conjunctival-scleral geometry